Our expanding view of platelet functions and its clinical implications

Journal of Cardiovascular Translational Research

Volumn 3, Issue 5, 2010, Pages 538-546

  Ombrello, Christopher ^a   Block, Robert C ^a   Morrell, Craig N ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b NONE

Author keywords

Activation; Aggregation; Inflammation; Platelet; Therapy; Thrombosis

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; APTAMER; CD36 ANTIGEN; CLOPIDOGREL; DOCOSAHEXAENOIC ACID; E 5555; ELINOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLUTAMIC ACID; ICOSAPENTAENOIC ACID; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; OMEGA 3 FATTY ACID; PLACEBO; PRASUGREL; PROTEINASE INHIBITOR; PURINERGIC RECEPTOR BLOCKING AGENT; RANTES; THIENOPYRIDINE DERIVATIVE; THROMBOCYTE FACTOR 4; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTERY DISEASE; ATHEROSCLEROSIS; BLEEDING; BONE MARROW APLASIA; CARDIOVASCULAR RISK; CELL STIMULATION; CELL TYPE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; GENE EXPRESSION REGULATION; HEART INFARCTION; HEMOSTASIS; HUMAN; INTRACELLULAR SIGNALING; MAINTENANCE THERAPY; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; RNA SPLICING; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOCYTOPOIESIS; THROMBOSIS; THROMBOSIS PREVENTION; UNSPECIFIED SIDE EFFECT; WILD TYPE;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; HEMORRHAGE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PLATELET AGGREGATION INHIBITORS; TRANSLATIONAL RESEARCH;

EID: 77958153263     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-010-9213-7     Document Type: Review

References (72)

1. RK Andrews MC Berndt 2004 Platelet physiology and thrombosis Thrombosis Research 114 5-6 447 453 10.1016/j.thromres.2004.07.020 15507277 1:CAS:528:DC%2BD2cXovVKms7o%3D (Pubitemid 39422578)
2. HR Buller T Ten Cate 1995 Coagulation and platelet activation pathways. A review of the key components and the way in which these can be manipulated European Heart Journal 16 Suppl L 8 10 8869012
3. LF Brass L Zhu TJ Stalker 2005 Minding the gaps to promote thrombus growth and stability Journal of Clinical Investigation 115 12 3385 3392 10.1172/JCI26869 16322784 1:CAS:528:DC%2BD2MXhtlSqtL3I (Pubitemid 43121823)
4. F Catella-Lawson 2001 Vascular biology of thrombosis: Platelet-vessel wall interactions and aspirin effects Neurology 57 5 Suppl 2 S5 S7 11552047 1:CAS:528:DC%2BD3MXntFGktLc%3D
5. DJ Fitzgerald 2001 Vascular biology of thrombosis: The role of platelet-vessel wall adhesion Neurology 57 5 Suppl 2 S1 S4 11552046 1:CAS:528:DC%2BD3MXntFGktLY%3D
6. I Fuse 1996 Disorders of platelet function Critical Reviews in Oncology/Hematology 22 1 1 25 10.1016/1040-8428(94)00167-7 8672250 1:STN:280:DyaK283jtV2qsw%3D%3D (Pubitemid 26027369)
7. SR Coughlin 1994 Molecular mechanisms of thrombin signaling Seminars in Hematology 31 4 270 277 7831572 1:CAS:528:DyaK2MXit1Wksbo%3D
8. SR Coughlin 2005 Protease-activated receptors in hemostasis, thrombosis and vascular biology Journal of Thrombosis and Haemostasis 3 8 1800 1814 10.1111/j.1538-7836.2005.01377.x 16102047 1:CAS:528:DC%2BD2MXpsFKjs7w%3D (Pubitemid 41716567)
9. M Gawaz H Langer AE May 2005 Platelets in inflammation and atherogenesis Journal of Clinical Investigation 115 12 3378 3384 10.1172/JCI27196 16322783 1:CAS:528:DC%2BD2MXhtlSqtL3P (Pubitemid 43121822)
10. K Srivastava DJ Field A Aggrey M Yamakuchi CN Morrell 2010 Platelet factor 4 regulation of monocyte klf4 in experimental cerebral malaria PLoS ONE 5 5 e10413 10.1371/journal.pone.0010413 10.1371/journal.pone.0010413 20454664 1:CAS:528:DC%2BC3cXmtV2ltLk%3D
11. C Weber 2005 Platelets and chemokines in atherosclerosis: Partners in crime Circulation Research 96 6 612 616 10.1161/01.RES.0000160077.17427.57 15802619 1:CAS:528:DC%2BD2MXis1elsLw%3D (Pubitemid 40478327)
12. A Zarbock RK Polanowska-Grabowska K Ley 2007 Platelet-neutrophil- interactions: Linking hemostasis and inflammation Blood Reviews 21 2 99 111 10.1016/j.blre.2006.06.001 16987572 1:CAS:528:DC%2BD2sXlsFGlu7Y%3D (Pubitemid 46428465)
13. CN Morrell H Sun AM Swaim WM Baldwin 3rd 2007 Platelets an inflammatory force in transplantation American Journal of Transplantation 7 11 2447 2454 10.1111/j.1600-6143.2007.01958.x 17927608 1:CAS:528:DC%2BD2sXhtlakt7zK (Pubitemid 47561602)
14. AD Kirk CN Morrell WM Baldwin 3rd 2009 Platelets influence vascularized organ transplants from start to finish American Journal of Transplantation 9 1 14 22 10.1111/j.1600-6143.2008.02473.x 19067663 1:STN:280: DC%2BD1M%2Fmt1yntA%3D%3D
15. K Srivastava IA Cockburn A Swaim LE Thompson A Tripathi CA Fletcher, et al. 2008 Platelet factor 4 mediates inflammation in experimental cerebral malaria Cell Host & Microbe 4 2 179 187 10.1016/j.chom.2008.07.003 1:CAS:528:DC%2BD1cXhtVGqsbjN
16. PA Lang C Contaldo P Georgiev AM El-Badry M Recher M Kurrer, et al. 2008 Aggravation of viral hepatitis by platelet-derived serotonin Natural Medicines 14 7 756 761 10.1038/nm1780 10.1038/nm1780 1:CAS:528:DC%2BD1cXotF2lurs%3D (Pubitemid 351951519)
17. S Massberg I Konrad K Schurzinger M Lorenz S Schneider D Zohlnhoefer, et al. 2006 Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo The Journal of Experimental Medicine 203 5 1221 1233 10.1084/jem.20051772 16618794 1:CAS:528:DC%2BD28XkvFWiurg%3D (Pubitemid 43736592)
18. M Gawaz 2004 Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium Cardiovascular Research 61 3 498 511 10.1016/j.cardiores. 2003.11.036 14962480 1:CAS:528:DC%2BD2cXhtFWmsLs%3D (Pubitemid 38210155)
19. H Langer AE May K Daub U Heinzmann P Lang M Schumm, et al. 2006 Adherent platelets recruit and induce differentiation of murine embryonic endothelial progenitor cells to mature endothelial cells in vitro Circulation Research 98 2 e2 e10 10.1161/01.RES.0000201285.87524.9e 16373597 1:CAS:528: DC%2BD28Xnt1GjsA%3D%3D
20. P von Hundelshausen KS Weber Y Huo AE Proudfoot PJ Nelson K Ley, et al. 2001 Rantes deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium Circulation 103 13 1772 1777 (Pubitemid 32291415)
21. A Reheman S Tasneem H Ni CP Hayward 2010 Mice with deleted multimerin 1 and alpha-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1 Thrombosis Research 125 5 e177 e183 10.1016/j.thromres.2010.01.009 10.1016/j.thromres.2010.01.009 20138333 1:CAS:528:DC%2BC3cXlt1ajt7o%3D
22. AW Michell LM Luheshi RA Barker 2005 Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease Neuroscience Letters 381 3 294 298 10.1016/j.neulet.2005.02.030/S0304-3940(05)00206-5 10.1016/j.neulet.2005.02.030 15896487 1:CAS:528:DC%2BD2MXkt1Ggtrg%3D
23. H Ehrenreich M Hasselblatt F Knerlich N von Ahsen S Jacob S Sperling, et al. 2005 A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain Proceedings of the National Academy of Sciences of the United States of America 102 3 862 867 10.1073/pnas.0406008102 10.1073/pnas.0406008102 15642952 1:CAS:528:DC%2BD2MXis1Cqtr0%3D (Pubitemid 40282756)
24. C Ferrarese C Zoia N Pecora R Piolti M Frigo G Bianchi, et al. 1999 Reduced platelet glutamate uptake in parkinson's disease Journal of Neural Transmission 106 7-8 685 692 10.1007/s007020050189 10907727 1:CAS:528: DyaK1MXmsl2hu7s%3D (Pubitemid 29401356)
25. CN Morrell H Sun M Ikeda JC Beique AM Swaim E Mason, et al. 2008 Glutamate mediates platelet activation through the ampa receptor The Journal of Experimental Medicine 205 3 575 584 10.1084/jem.20071474 18283118 (Pubitemid 351439305)
26. H Sun A Swaim JE Herrera D Becker L Becker K Srivastava, et al. 2009 Platelet kainate receptor signaling promotes thrombosis by stimulating cyclooxygenase activation Circulation Research 105 595 603 10.1161/CIRCRESAHA. 109.198861 19679838 1:CAS:528:DC%2BD1MXhtVygurfP
27. C Ferrarese G Sala R Riva B Begni C Zoia L Tremolizzo, et al. 2001 Decreased platelet glutamate uptake in patients with amyotrophic lateral sclerosis Neurology 56 2 270 272 11160972 1:STN:280:DC%2BD3M7pt1ygtg%3D%3D (Pubitemid 32095377)
28. M Berk H Plein D Ferreira 2001 Platelet glutamate receptor supersensitivity in major depressive disorder Clinical Neuropharmacology 24 3 129 132 10.1097/00002826-200105000-00002 11391122 1:CAS:528:DC%2BD3MXkvVOnsr0%3D (Pubitemid 32549986)
29. MM Denis ND Tolley M Bunting H Schwertz H Jiang S Lindemann, et al. 2005 Escaping the nuclear confines: Signal-dependent pre-mrna splicing in anucleate platelets Cell 122 3 379 391 10.1016/j.cell.2005.06.015 16096058 1:CAS:528:DC%2BD2MXovV2qsrY%3D (Pubitemid 41127140)
30. P Landry I Plante DL Ouellet MP Perron G Rousseau P Provost 2009 Existence of a microrna pathway in anucleate platelets Nature Structural & Molecular Biology 16 9 961 966 10.1038/nsmb.1651 1:CAS:528:DC%2BD1MXps1ahtbc%3D
31. Y Huo KF Ley 2004 Role of platelets in the development of atherosclerosis Trends in Cardiovascular Medicine 14 1 18 22 10.1016/j.tcm.2003.09.007 14720470 1:CAS:528:DC%2BD2cXjsVykug%3D%3D (Pubitemid 38068207)
32. Y Huo A Schober SB Forlow DF Smith MC Hyman S Jung, et al. 2003 Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein e Natural Medicines 9 1 61 67 10.1038/nm810 1:CAS:528: DC%2BD3sXjtVSg (Pubitemid 36098261)
33. JJ Michiels M Gawaz 2007 Preface: platelets in inflammation and atherothrombosis Seminars in Thrombosis and Hemostasis 33 2 119 122 10.1055/s-2007-969024 17340458 (Pubitemid 46427752)
34. EA Podrez TV Byzova M Febbraio RG Salomon Y Ma M Valiyaveettil, et al. 2007 Platelet cd36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype Natural Medicines 13 9 1086 1095 10.1038/nm1626 1:CAS:528: DC%2BD2sXhtVSgtrrF (Pubitemid 47517507)
35. K Chen M Febbraio W Li RL Silverstein 2008 A specific cd36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein Circulation Research 102 12 1512 1519 10.1161/CIRCRESAHA.108.172064 18497330 1:CAS:528:DC%2BD1cXmvFOhtrw%3D
36. -/- mice Thrombosis and Haemostasis 98 5 1108 1113 18000617 1:CAS:528:DC%2BD2sXhsVWrsbbO
37. RR Koenen P von Hundelshausen IV Nesmelova A Zernecke EA Liehn A Sarabi, et al. 2009 Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice Natural Medicines 15 1 97 103 10.1038/nm.1898 1:CAS:528:DC%2BD1MXhtVOqsA%3D%3D
38. BJ McMorran VM Marshall C de Graaf KE Drysdale M Shabbar GK Smyth, et al. 2009 Platelets kill intraerythrocytic malarial parasites and mediate survival to infection Science 323 5915 797 800 10.1126/science.1166296 19197068 1:CAS:528:DC%2BD1MXhtlertr4%3D
39. E Boilard PA Nigrovic K Larabee GF Watts JS Coblyn ME Weinblatt, et al. 2010 Platelets amplify inflammation in arthritis via collagen-dependent microparticle production Science 327 5965 580 583 10.1126/science.1181928 20110505 1:CAS:528:DC%2BC3cXhtVGmur8%3D
40. H Xu X Zhang RB Mannon AD Kirk 2006 Platelet-derived or soluble cd154 induces vascularized allograft rejection independent of cell-bound cd154 Journal of Clinical Investigation 116 3 769 774 10.1172/JCI27155 16498500 1:CAS:528:DC%2BD28XitlGktbo%3D (Pubitemid 43326886)
41. CN Morrell K Murata AM Swaim E Mason TV Martin LE Thompson, et al. 2008 In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody Circulation Research 102 7 777 785 10.1161/CIRCRESAHA.107.170332 18296616 1:CAS:528:DC%2BD1cXktV2ksro%3D (Pubitemid 351521583)
42. C Patrono LA Garcia Rodriguez R Landolfi C Baigent 2005 Low-dose aspirin for the prevention of atherothrombosis The New England Journal of Medicine 353 22 2373 2383 10.1056/NEJMra052717/353/22/2373 10.1056/NEJMra052717 16319386 1:CAS:528:DC%2BD2MXht1OmsbnM
43. PA Gurbel US Tantry 2010 Combination antithrombotic therapies Circulation 121 4 569 583 10.1161/CIRCULATIONAHA.109.853085 10.1161/CIRCULATIONAHA.109. 853085 20124137
44. A Symeonidis A Kouraklis-Symeonidis U Seimeni A Galani N Giannakoulas E Fragopanagou, et al. 2002 Ticlopidine-induced aplastic anemia: Two new case reports, review, and meta-analysis of 55 additional cases American Journal of Hematology 71 1 24 32 10.1002/ajh.10150 10.1002/ajh.10150 12221670 1:CAS:528:DC%2BD38XnsVOhsb4%3D (Pubitemid 34988582)
45. ME Bertrand HJ Rupprecht P Urban AH Gershlick 2000 Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (classics) Circulation 102 6 624 629 10931801 1:CAS:528:DC%2BD3cXlvFyms7g%3D
46. P Staritz K Kurz M Stoll E Giannitsis HA Katus BT Ivandic 2009 Platelet reactivity and clopidogrel resistance are associated with the h2 haplotype of the p2y12-adp receptor gene International Journal of Cardiology 133 3 341 345 10.1016/j.ijcard.2007.12.118 10.1016/j.ijcard.2007.12.118 18485500
47. A De Miguel B Ibanez JJ Badimon 2008 Clinical implications of clopidogrel resistance Thrombosis and Haemostasis 100 2 196 203 08080196 18690337
48. JS Hulot A Bura E Villard M Azizi V Remones C Goyenvalle, et al. 2006 Cytochrome p450 2c19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 7 2244 2247 10.1182/blood-2006-04-013052 10.1182/blood-2006-04-013052 16772608 1:CAS:528:DC%2BD28XhtVCgur7I (Pubitemid 44497506)
49. JT Brandt SL Close SJ Iturria CD Payne NA Farid CS Ernest 2nd, et al. 2007 Common polymorphisms of cyp2c19 and cyp2c9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel Journal of Thrombosis and Haemostasis 5 12 2429 2436 10.1111/j.1538-7836.2007.02775.x/JTH2775 10.1111/j.1538-7836.2007.02775.x 17900275 1:CAS:528:DC%2BD1cXivFGj
50. JL Mega SL Close SD Wiviott L Shen RD Hockett JT Brandt, et al. 2009 Cytochrome p-450 polymorphisms and response to clopidogrel The New England Journal of Medicine 360 4 354 362 10.1056/NEJMoa0809171 10.1056/NEJMoa0809171 19106084 1:CAS:528:DC%2BD1MXhtVSlsbs%3D
51. T Simon C Verstuyft M Mary-Krause L Quteineh E Drouet N Meneveau, et al. 2009 Genetic determinants of response to clopidogrel and cardiovascular events The New England Journal of Medicine 360 4 363 375 10.1056/NEJMoa0808227 10.1056/NEJMoa0808227 19106083 1:CAS:528:DC%2BD1MXhtVSlsbY%3D
52. L Bonello L Camoin-Jau S Armero O Com S Arques C Burignat-Bonello, et al. 2009 Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis The American Journal of Cardiology 103 1 5 10 10.1016/j.amjcard.2008.08.048/S0002-9149(08)01412-4 10.1016/j.amjcard.2008.08.048 19101221 1:CAS:528:DC%2BD1cXhsFajsr%2FP
53. N Tavassoli S Voisin D Carrie M Lapeyre-Mestre M Galinier JL Montastruc, et al. 2010 High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients American Journal of Cardiovascular Drugs 10 1 29 35 10.2165/11318260-000000000-00000/4 10.2165/11318260-000000000-00000 20104932 1:CAS:528:DC%2BC3cXksFGiuro%3D
54. SD Wiviott E Braunwald CH McCabe I Horvath M Keltai JP Herrman, et al. 2008 Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the triton-timi 38 trial: A subanalysis of a randomised trial Lancet 371 9621 1353 1363 10.1016/S0140-6736(08)60422-5/S0140-6736(08)60422-5 10.1016/S0140-6736(08)60422- 5 18377975 1:CAS:528:DC%2BD1cXkvVyisro%3D
55. AD Michelson AL Frelinger 3rd E Braunwald WE Downey DJ Angiolillo NP Xenopoulos, et al. 2009 Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the triton-timi 38 trial European Heart Journal 30 14 1753 1763 10.1093/eurheartj/ehp159 10.1093/eurheartj/ehp159 19435740 1:CAS:528:DC%2BD1MXptVCjt7c%3D
56. DJ Moliterno 2008 Advances in antiplatelet therapy for acs and pci Journal of Interventional Cardiology 21 Suppl 1 S18 S24 10.1111/j.1540-8183. 2008.00409.x/JOIC409 10.1111/j.1540-8183.2008.00409.x 19090933
57. M Roffi DJ Moliterno B Meier ER Powers CL Grines PM DiBattiste, et al. 2002 Impact of different platelet glycoprotein iib/iiia receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do tirofiban and reopro give similar efficacy outcomes trial (target) 1-year follow-up Circulation 105 23 2730 2736 10.1161/01.CIR.0000018123.02672.C7 12057986 1:CAS:528:DC%2BD38Xlt1ykurY%3D (Pubitemid 34615143)
58. AG Tuhta O Yesildag D Koprulu 2006 Tirofiban-associated acute thrombocytopenia Acta Cardiologica 61 5 577 579 10.2143/AC.61.5.2017776 17117761 (Pubitemid 44622162)
59. JS Berger MT Roe CM Gibson R Kilaru CL Green L Melton, et al. 2009 Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible p2y12 adp-receptor antagonist, before primary percutaneous intervention in patients with st-elevation myocardial infarction: The early rapid reversal of platelet thrombosis with intravenous elinogrel before pci to optimize reperfusion in acute myocardial infarction (erase mi) pilot trial American Heart Journal 158 6 998 1004 10.1016/j.ahj.2009.10.010 19958867 1:CAS:528:DC%2BD1MXhsFagsrzP e1001
60. L Wallentin RC Becker A Budaj CP Cannon H Emanuelsson C Held, et al. 2009 Ticagrelor versus clopidogrel in patients with acute coronary syndromes The New England Journal of Medicine 361 11 1045 1057 10.1056/NEJMoa0904327 10.1056/NEJMoa0904327 19717846 1:CAS:528:DC%2BD1MXhtFaltL%2FJ
61. S Goto T Yamaguchi Y Ikeda K Kato H Yamaguchi P Jensen 2010 Safety and exploratory efficacy of the novel thrombin receptor (par-1) antagonist sch530348 for non-st-segment elevation acute coronary syndrome Journal of Atherosclerosis and Thrombosis 17 2 156 164 JST.JSTAGE/jat/3038 20124733
62. VL Serebruany M Kogushi D Dastros-Pitei M Flather DL Bhatt 2009 The in-vitro effects of e5555, a protease-activated receptor (par)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease Thrombosis and Haemostasis 102 1 111 119 10.1160/TH08-12-0805 19572075 1:CAS:528:DC%2BD1MXptlemurg%3D
63. G Gajos P Rostoff A Undas W Piwowarska 2010 Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: The omega-pci (omega-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study Journal of the American College of Cardiology 55 16 1671 1678 10.1016/j.jacc.2009.11.080/S0735-1097(10)00591-7 10.1016/j.jacc.2009.11.080 20394870 1:CAS:528:DC%2BC3cXmsVKnsbk%3D
64. EI Lev D Leshem-Lev A Mager H Vaknin-Assa N Harel Y Zimra, et al. 2010 Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis European Heart Journal 10.1093/eurheartj/ehq184 20543191
65. EI Lev A Solodky N Harel A Mager D Brosh A Assali, et al. 2010 Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation Journal of the American College of Cardiology 55 2 114 121 10.1016/j.jacc.2009.08.039/S0735-1097(09)03380-4 10.1016/j.jacc.2009.08.039 20117379 1:CAS:528:DC%2BC3cXhvFWrur4%3D
66. PD Watson PS Joy C Nkonde SE Hessen DG Karalis 2009 Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel-versus- aspirin + clopidogrel in patients with cardiovascular disease The American Journal of Cardiology 104 8 1052 1054 10.1016/j.amjcard.2009.05.055/S0002- 9149(09)01178-3 10.1016/j.amjcard.2009.05.055 19801023 1:CAS:528: DC%2BD1MXht1WntbjF
67. S Oney SM Nimjee J Layzer N Que-Gewirth D Ginsburg RC Becker, et al. 2007 Antidote-controlled platelet inhibition targeting von willebrand factor with aptamers Oligonucleotides 17 3 265 274 10.1089/oli.2007.0089 10.1089/oli.2007.0089 17854267 1:CAS:528:DC%2BD2sXhtVakt7zK (Pubitemid 47463359)
68. CK Dyke SR Steinhubl NS Kleiman RO Cannon LG Aberle M Lin, et al. 2006 First-in-human experience of an antidote-controlled anticoagulant using rna aptamer technology: A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor ixa activity Circulation 114 23 2490 2497 10.1161/CIRCULATIONAHA.106.668434 10.1161/CIRCULATIONAHA.106.668434 17101847 1:CAS:528:DC%2BD28Xht1Cqur3M (Pubitemid 44901522)
69. SM Nimjee CP Rusconi RA Harrington BA Sullenger 2005 The potential of aptamers as anticoagulants Trends in Cardiovascular Medicine 15 1 41 45 10.1016/j.tcm.2005.01.002/S1050-1738(05)00003-4 10.1016/j.tcm.2005.01.002 15795162 1:CAS:528:DC%2BD2MXjt1ajtbY%3D
70. SM Nimjee CP Rusconi BA Sullenger 2005 Aptamers: An emerging class of therapeutics Annual Review of Medicine 56 555 583 10.1146/annurev.med.56.062904. 144915 10.1146/annurev.med.56.062904.144915 15660527 1:CAS:528: DC%2BD2MXisVSrt7w%3D (Pubitemid 40299797)
71. CP Rusconi JD Roberts GA Pitoc SM Nimjee RR White G Quick Jr, et al. 2004 Antidote-mediated control of an anticoagulant aptamer in vivo Nature Biotechnology 22 11 1423 1428 10.1038/nbt1023 10.1038/nbt1023 15502817 1:CAS:528:DC%2BD2cXptlSls7o%3D (Pubitemid 39482862)
72. RC Becker S Oney KC Becker B Sullenger 2009 Antidote-controlled antithrombotic therapy targeting factor ixa and von willebrand factor Annals of the New York Academy of Sciences 1175 61 70 10.1111/j.1749-6632.2009.05017.x/ NYAS5017 10.1111/j.1749-6632.2009.05017.x 19796078 1:CAS:528:DC%2BD1MXhtlGgu7zF